{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:27:33Z","timestamp":1783006053229,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.nmd.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T11:32:59Z","timestamp":1559907179000},"page":"554-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis"],"prefix":"10.1016","volume":"29","author":[{"given":"Ricardo H.","family":"Roda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leana","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Corse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2019.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.06.002_bib0003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2019.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.06.002_bib0006","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0007","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.06.002_bib0011","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nmd.2019.06.002_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2019.06.002_bib0013","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2019.06.002_bib0014","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2019.06.002_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteriod treatment of myasthenia gravis: report of 116 Patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2019.06.002_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an Anti-CD20 Monoclonal Antibody: history and Mechanism of Action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transpl"},{"key":"10.1016\/j.nmd.2019.06.002_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review: rituximab in myasthenia gravis","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.06.002_bib0018","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2019.06.002_bib0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.06.002_bib0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2019.06.002_bib0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2019.06.002_bib0022","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.06.002_bib0023","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.06.002_bib0024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2019.06.002_bib0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.06.002_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mus.24694","article-title":"Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis: use of MMF in MG","volume":"52","author":"Hobson-Webb","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.06.002_bib0027","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618313038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618313038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:14Z","timestamp":1760774894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896618313038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0960896618313038"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.06.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}